Mayne Pharma Group Limited
Mayne Pharma Group Limited (MAYNF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
maynf · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Mayne Pharma Group Limited (MAYNF) measures how much investors pay for each dollar of the company's trailing earnings. MAYNF's current PE ratio of N/A is calculated by dividing its stock price of $1.55 by its TTM earnings per share of -$1.02.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 8 fiscal years · Front-end computedMinQ1 · 25%1.1x
MedianQ3 · 75%4.5x
Max
At N/A, MAYNF's current P/E is lower than in 0% of its annual fiscal year readings over the past 8 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Mayne Pharma Group LimitedYou MAYNF | $126M | N/A | — | -$1.02 |
 American Oncology Network, Inc. AONC | $351M | N/A | — | -$0.29 |
 Benchmark Holdings plc BHCCF | $225M | N/A | — | -$0.05 |
 Craftport Cannabis Corp. BHHKF | $0M | N/A | — | -$0.49 |
 Cipher Pharmaceuticals Inc. CPHRF | $307M | 10.06x | — | $1.09 |
 China Evergrande New Energy Vehicle Group Limited EVGRF | $2M | N/A | — | -$1.10 |
 Hansa Biopharma AB (publ) HNSBF | $246M | N/A | — | -$6.58 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | — | $-1.14 | — | |
2024-06-30 FY2024 | — | $-2.12 | — | |
2023-06-30 FY2023 | 2.70x | $1.43 | — | |
2022-06-30 FY2022 | — | $-2.55 | — | |
2021-06-30 FY2021 | — | $-2.65 | — | |
2020-06-30 FY2020 | — | $-1.21 | — | |
2019-06-30 FY2019 | — | $-3.81 | — | |
2018-06-30 FY2018 | — | $-1.83 | — | |
2017-06-30 FY2017 | 0.91x | $1.24 | -59.4% | |
2016-06-30 FY2016 | 2.25x | $0.95 | -50.3% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Mayne Pharma Group Limited (MAYNF) measures how much investors pay for each dollar of the company's trailing earnings. MAYNF's current PE ratio of N/A is calculated by dividing its stock price of $1.55 by its TTM earnings per share of -$1.02.
Frequently asked questions
MAYNF pe ratio · 6 questionsMAYNF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.55 and TTM EPS of -$1.02. Data sourced from Financial Modeling Prep via MAYNF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Mayne Pharma Group Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09